01—Abstract
Summary
Summary of the 8-K filed August 7, 2024. Cited figures are marked; the original filing is the authoritative source.
CVS Health reported second-quarter 2024 results on August 7, 2024 that fell well short of prior-year levels in profitability, even as revenue grew.
Total revenues rose 2.6% to $91.2 billion, but GAAP diluted EPS declined to $1.41a from $1.48 and Adjusted EPS fell 17% to $1.83 from $2.21. Adjusted operating income dropped 16.4% to $3.74 billion, driven mainly by the Health Care Benefits segment, where the medical benefit ratio (MBR) rose to 89.6% from 86.2% on higher utilization, the unfavorable Medicare Advantage star ratings impact for the 2024 payment year, higher Medicaid acuity, and an exchange risk adjustment change in estimate. Health Care Benefits adjusted operating income fell 39.1% year over year.
The more consequential news for investors is the guidance cut. Management lowered full-year 2024 GAAP diluted EPS guidance to $4.95b–$5.20 from at least $5.64, Adjusted EPS guidance to $6.40–$6.65 from at least $7.00, and cash flow from operations guidance to approximately $9.0 billion from at least $10.5 billion. The company attributed the revision to continued pressure in Health Care Benefits, partially offset by strong performance in Health Services and Pharmacy & Consumer Wellness.
Management also announced immediate leadership changes: Brian Kane is departing, CEO Karen Lynch will directly oversee the Health Care Benefits segment alongside CFO Tom Cowhey, and Katerina Guerraz will serve as segment COO. Offsetting the weakness, Health Services adjusted operating income rose 1.1% despite a 8.8% revenue decline tied to the loss of a large client, and year-to-date operating cash flow was $8.0 billionc.
The filing's financial statements and the Exhibit 99.1 press release are furnished under Item 2.02 rather than filed, so they are not subject to Section 18 liability. Investors should weigh the sharp earnings reset and the Health Care Benefits turnaround risk against the steadier performance in the pharmacy and services segments.
02—Key points
Key Highlights
- Q2 2024 Adjusted EPS of $1.83 declined 17% from $2.21 a year earlier; GAAP diluted EPS fell to $1.41 from $1.48.
- Full-year 2024 Adjusted EPS guidance cut to $6.40–$6.65 from at least $7.00 (about 7–9% reduction at the midpoint), with GAAP EPS guidance lowered to $4.95–$5.20 from at least $5.64.
- Health Care Benefits MBR rose 340 bps to 89.6%, driven by utilization, Medicare Advantage star ratings impact, and Medicaid acuity; segment adjusted operating income fell 39.1%.
- Full-year 2024 operating cash flow guidance lowered to about $9.0 billion from at least $10.5 billion; year-to-date operating cash flow was $8.0 billion.
- Leadership changes: Brian Kane exits; CEO Karen Lynch assumes direct oversight of Health Care Benefits with CFO Tom Cowhey; Katerina Guerraz named segment COO.
- Health Services adjusted operating income rose 1.1% to $1.9 billion despite a 8.8% revenue decline from the loss of a large client; pharmacy claims processed fell 18.3%.
- Pharmacy & Consumer Wellness revenue grew 3.7%, but adjusted operating income fell 12.0% on reimbursement pressure and weaker front-store sales.
03—Questions
Frequently Asked Questions
Why did CVS cut its 2024 earnings guidance?
The cut reflects continued pressure in the Health Care Benefits segment, where higher medical utilization, the unfavorable Medicare Advantage star ratings impact for the 2024 payment year, higher Medicaid acuity from the resumption of redeterminations, and an exchange risk adjustment change in estimate drove the MBR up to 89.6%. Partial offsets came from the Health Services and Pharmacy & Consumer Wellness segments.
How significant is the revised guidance relative to prior expectations?
Adjusted EPS guidance was lowered to $6.40–$6.65 from at least $7.00, a reduction of roughly $0.35–$0.60 per share. GAAP diluted EPS guidance dropped to $4.95–$5.20 from at least $5.64, and operating cash flow guidance fell by about $1.5 billion to roughly $9.0 billion.
What is the Health Care Benefits segment's outlook and who is responsible for fixing it?
The filing does not provide a specific recovery timeline. Management said it is making leadership changes effective immediately, with CEO Karen Lynch directly leading the segment and CFO Tom Cowhey overseeing day-to-day management alongside her. Katerina Guerraz, a 20-year Aetna veteran, was named segment COO. Investors should watch whether MBR improves in subsequent quarters.
Were there any one-time items that affected Q2 results?
Q2 2024 GAAP results included about $102 million of acquisition-related integration costs and $90 million of net realized capital losses, which are excluded from Adjusted EPS. The effective tax rate fell to 24.3% from 25.5% due to a state tax settlement, which helped results. The prior-year quarter included a $496 million restructuring charge, which is not repeated this year.
Is the Health Services business still growing?
Health Services adjusted operating income rose 1.1% in Q2 to $1.9 billion, supported by improved purchasing economics, though revenue fell 8.8% because of the previously announced loss of a large client and continued pharmacy price concessions. Management cited the segment as a source of strength in the guidance revision.
04—Continue